CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

ABSTRACT:

Purpose

A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation to endoxifen. Studies have provided conflicting data, and meta-analyses suggest a small but significant increase in cancer recurrence, necessitating additional studies to allow for accurate effect assessment. We conducted a retrospective pharmacogenomic analysis of a prospectively collected community-based cohort of patients with estrogen receptor-positive breast cancer to test for associations between low-activity CYP2D6 genotype and disease outcome in 500 patients treated with adjuvant tamoxifen monotherapy and 500 who did not receive any systemic adjuvant therapy.

SUBMITTER: Hertz DL 

PROVIDER: S-EPMC6028015 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature